One Drop (OD) provides self-care support via an evidence-based mobile app, a Bluetooth-connected glucometer and testing supplies, and in-app coaching from CDEs. The app with coaching is associated with a 0.9 to 1.3% lab hemoglobin (A1c) improvement over 3 months. The full solution is associated with a 1.9% eA1c improvement over 3 months. We enrolled people with diabetes to participate in an IRB-approved study examining OD’s long-term effect on A1c. Adults with lab-verified ≥ 7.0% A1c and no prior OD account participated in a single-group longitudinal study. Participants used OD for an average 7.7 months. Lab A1c was assessed at baseline, 3, and 8 months. Descriptive statistics characterized the sample. Repeated measures ANOVA tested A1c change over time. Bonferroni-corrected post hoc tests examined A1c change between timepoints. Participants (N = 10) were 53 ± 7 years old and half female. Sphericity was assumed (Mauchly’s W = .30, p = .05). A1c significantly changed over time, F(2, 12) = 5.62, p < 0.019, partial eta = .48 (see Figure 1). When adjusted for multiple comparisons, baseline to 3-mo A1c change (MDiff = .64%, p = .10) and 3-mo to 8-mo Alc change trended significant (MDiff = 1.74 %, p = .10). Using OD for up to 8 months is associated with improved A1c. This is the first OD study to observe participants beyond 3 months and collect multiple measures of lab A1c over time. An accumulation of non-experimental and experimental evidence suggests OD improves A1c among people with diabetes.

Disclosure

A. Hirsch: Employee; Self; Informed Data Systems Inc. Research Support; Self; Fitbit, Inc., MannKind Corporation. Stock/Shareholder; Self; Informed Data Systems Inc. C.Y. Osborn: Employee; Self; One Drop. M. Heyman: Consultant; Self; Lexicon Pharmaceuticals, Inc., Lilly Diabetes, Tandem Diabetes Care. Employee; Self; One Drop. B. Huddleston: Employee; Self; One Drop. J. Dachis: Stock/Shareholder; Self; Informed Data Systems Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.